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Experience of telemedicine use in a big cohort 
of patients with rheumatoid arthritis during 
COVID-19 pandemic
We have read with interest the work of Bozzalla- Cassione et al1 
published recently in your journal regarding the implementation of a 
telemedicine programme for patients with lupus in northern Italy. It is 
logical to suppose that the risk of patients with rheumatic diseases of 
having a more severe clinical course if they become infected with the 
COVID-19 infection is very high; however, although some of the reports 
show that there seems to be a low incidence of COVID-19 infection in 
patients with rheumatic disease, collaborative work with large cohorts is 
needed, which could show us the real incidence of COVID-19 infection 
in these patients and what happens with the establishment of telemedi-
cine programmes.2–6
We show an experience in a specialised centre in Bogota, Colombia; 
currently, we have a cohort of 5597 patients with rheumatoid arthritis 
(RA) in exclusively ambulatory care. On 12 March 2020, in Colombia, 
the health emergency by COVID-19 was established and a week later 
the Ministry of Health ordered the outpatient care procedure for the 
population in isolation. From that moment on, our institution, carrying 
out the proper logistical and legal processes, proceeded to convert its 
ambulatory care services into care through telemedicine.
By telecounselling, patients were offered consultation by telemed-
icine due to the high epidemiological risk of COVID-19; the patient 
gave informed consent to accept it or otherwise to request a face- to- face 
consultation despite the epidemiological risk warning; a third option was 
that the patient did not accept telemedicine or face- to- face consultation 
for personal reasons.
Here, we report the outcomes since 21 March–16 May (8 weeks later). 
For rheumatology care, the doctor must request informed consent for 
the consultation; then a standardised protocol was applied both for RA 
and also for suspected symptoms of COVID-19; as a measure of disease 
activity Patient Activity Score (PAS) was applied, and Health Assessment 
Questionnaire (HAQ) was also evaluated. When during the consultation 
the doctor finds that there is potentially high activity of the disease, a 
face- to- face consultation was ordered. In case of need, patients are sent 
to telemedicine consultation with the physiatrist or psychologist. For 
face- to- face consultation, standardised clinimetry instruments are used.
Until May the 16 (8 weeks later), 3503 patients have been followed 
up; 3228 (92%) have been seen by telemedicine and 275 (8%) by conven-
tional face- to- face consultation; of these patients, 55 (20%) men and 
220 (80%) women attended the face- to- face consultation; of patients 
attended by telemedicine, 567 (17.5%) were men and 2661 (82.5%) 
were women. Regarding COVID-19 infection, in 3 of the 275 patients 
who attended an in- person consultation, COVID-19 infection was 
suspected due to respiratory symptoms, but was finally ruled out. None 
of the patients seen so far by telemedicine had suspected COVID-19 by 
clinic or had contact with COVID-19 confirmed patients.
At first glance, these results seem surprising; there are zero incidences 
of COVID-19 infection in this large cohort of patients with RA, which 
we believe is due to the sanitary measures imposed by the country and 
to the adequate and standardised use of telemedicine. At first sight, we 
found that almost 75% of patients are well controlled regarding disease 
activity; however, the centre has started a mixed methodology study 
that includes a cohort study and a qualitative study to evaluate, whether 
telemedicine is effective in controlling disease activity of RA, such as 
the usual outpatient consultation. In this regard, there are some publi-
cations, but in the conditions of a pandemic like the present one, we do 
not have the evidence; on the other hand, it is necessary to evaluate the 
real incidence of COVID-19 infection in this group of patients and its 
clinical course.
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